You are here

The FDA Approves Dynacin (minocycline HCl) Tablets

SCOTTSDALE, Ariz.--(BUSINESS WIRE)--April 16, 2003--Medicis (NYSE:MRX - News) today announced the approval of an Abbreviated New Drug Application ("ANDA") by the Food and Drug Administration ("FDA") to market its new DYNACIN® Tablets (minocycline HCl). Minocycline is the most frequently prescribed drug by U.S. dermatologists and DYNACIN® is the number one prescribed brand of minocycline in the specialty of dermatology. Par Pharmaceutical, a wholly owned subsidiary of Pharmaceutical Resources, Inc. (NYSE:PRX - News) will manufacture new DYNACIN® Tablets for Medicis pursuant to an exclusive manufacturing and supply agreement. Financial terms of the agreement were undisclosed.

DYNACIN® Tablets is a prescription product and will be available in 50 mg., 75 mg. and 100 mg. dosages. DYNACIN® Tablets formulation is the most recent innovation to the DYNACIN® family of products. DYNACIN® Tablets is the only prescription minocycline tablet approved in the United States for the adjunctive treatment of severe acne.

In addition to being the only minocycline tablet on the market, new DYNACIN® Tablets are small, easy-to-swallow, coated tablets suitable for patients who experience difficulty swallowing larger-sized capsules. Additionally, DYNACIN® Tablets incorporates the same dye-free formulation as the capsules to avoid potential allergic reactions in patients with sensitivities to dye additives.

"We are pleased to announce approval of DYNACIN® Tablets, the only prescription minocycline tablet indicated for the adjunctive treatment of severe acne," said Jonah Shacknai, chairman and chief executive officer of Medicis. "Approval of this new dosage form of DYNACIN® has the potential to enhance the brand's already significant success. The new, smaller-sized, coated DYNACIN® Tablets are expected to offer a high degree of patient compliance by providing an easier to swallow form of the most widely prescribed brand of minocycline in dermatology."

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Acasti reports disappointing results for a second Omega-3-based drug
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks